Recent News
Immunis Chairman Dr. Hans Keirstead to Present at Abundance360
Immunis, Inc., a private biotechnology company with an innovative treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present at Abundance360 in Los Angeles. The annual conference was developed by the renowned medical leader Peter Diamandis, M.D., whose entrepreneurship encompasses topics of space, education, venture capital and longevity. Longevity research is currently one of science’s hottest areas of study and Abundance360 will cover this sector’s most critical breakthroughs.
Immunis Research Scientist Dr. Scott Greilach to Present at the Festival of Biologics in San Diego
Immunis, Inc., a private biotechnology company with a novel treatment for age and disease-related immune deficits, announces that its Research Scientist, Scott Greilach, Ph.D., will present at the Festival of Biologics in San Diego. With hundreds of world-class speakers, this three-day conference dissects the infrastructure of innovative biologics including discovery, development, manufacturing, pricing and market access. The conference’s goal is to harness the expertise from individuals in pharma, biotech and academic sectors to tackle the commercial challenges of bringing new therapies to market.
Immunis Chairman Dr. Hans Keirstead to Present at NextMed Health
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present a keynote at the annual NextMed Health conference in San Diego. This premier event was founded by Dr. Daniel Kraft, who has over 25 years of experience as an inventor, innovator, entrepreneur, investor and renowned speaker. Dr. Kraft’s expertise in the field of stem cell-based therapies also makes him an invaluable asset as Board Member of Immunis Inc.
Immunis, Inc., a private biotechnology company with an innovative treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present at the annual Global Life Science Partnering and Investor Conference in La Jolla, California.
Immunis Chairman Dr. Hans Keirstead to Present at 2023 BIO CEO and Investor Conference
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present at the 2023 BIO CEO and Investor Conference in New York. Dr. Keirstead is thrilled to discuss the recent milestones of Immunis’ Phase 1/2a clinical trial, which applies an investigational secretome product, STEM, in participants with muscle atrophy related to knee osteoarthritis.
Immunis Recruits Individuals with Muscle Atrophy for Phase 1/2a Clinical Trial
Immunis Inc. is a private biotechnology company recruiting participants between the ages of 50-75 with muscle atrophy related to knee osteoarthritis for its Phase 1/2a clinical trial. The trial will assess the safety and tolerability of Immunis’ investigational secretome product designed to benefit immune system modulation and health.
Immunis Inc. Featured by DelveInsight for Recent Developments in Knee Osteoarthritis Research
Immunis Inc. was featured by DelveInsight Business Research LLP as one of the six companies with recent developments in researching a treatment for knee osteoarthritis. DelveInsight is a leading Business Consultant and Market Research Firm that examines the innovative landscape of the healthcare industry to inform decision-makers on critical issues and opportunities. For more information about the article, read here.
Immunis Chairman Dr. Hans Keirstead to Present at the 2023 Biotech Showcase
Immunis, Inc., a private biotech company generating a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present at the annual Biotech Showcase in San Francisco. Dr. Keirstead will share the latest advancements of Immunis’ investigational secretome product, STEM, highlighting the Phase 1/2a clinical trial's first-in-human injection milestone.
Immunis Featured in Lifespan.io
Immunis Inc.'s press release announcing the first-in-human injection of STEM was highlighted by Lifespan.io, an online news source for breakthrough technologies and scientific discoveries in aging and longevity. The article is entitled "Immunis Begins Clinical Trial of Stem Cell Secretome." The high-level, scientific content for Lifespan.io is supported by The Lifespan Extension Advocacy Foundation (LEAF), a 501(c)(3) non-profit organization promoting fundamental research on aging and age-related diseases, as well as educating the public on the possibility of preventing age-related diseases.
Immunis Announces First-in-Human Injection of Secretome Product for Age-Related Muscle Atrophy
Immunis, Inc., a private biotech company developing an innovative treatment for age and disease-related immune decline, announces its first-in-human injection of IMM01-STEM for its STEM-MYO Phase 1/2a clinical trial. The goal is to assess the safety and tolerability of Immunis’ investigational stem cell secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease contributing to age-related disability. Immunis is actively recruiting patients for the trial in collaboration with the California Institute of Regenerative Medicine (CIRM) Alpha Clinic.
Immunis Chairman Dr. Hans Keirstead Appointed to Board of Directors of the Human Immunome Project
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., was appointed to the Board of Directors of the Human Immunome Project. The Human Immunome Project is a global initiative that combines breakthrough advances in biomedicine and artificial intelligence to provide a more sophisticated understanding of human immunity and disease. An elite team of scientists are using AI to compile and assess the largest dataset of biomedicine to create superior models of immune system function and precision drug targeting, thus facilitating diagnosis and treatment of disease.
Immunis, Inc. Chairman, Dr. Hans Keirstead, presented at the 2022 Festival of Biologics Conference in Basel, Switzerland. The Festival of Biologics is a leading international event for drug discovery, development, manufacturing and marketing for clinical trials. Please enjoy these photos from the event.
Immunis Featured in NEO.LIFE Magazine
Immunis Inc was featured in an article by NEO.LIFE magazine entitled, "Sarcopenia: What a waste." NEO.LIFE was founded by Jane Metcalfe, the co-founder and former president or Wired magazine.
Immunis Chairman Dr. Hans Keirstead Recognized as a Top Orange County Business Leader
Immunis, Inc., a private biotech company generating a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., was recognized as one of Orange County Business Journal’s OC 500, a list that includes the most influential individuals in Orange County. Honorees are selected on a merit basis after extensive evaluation and include top executives, government figures, philanthropists, and other civic representatives who contribute to the community of business.
Immunis Chairman, Dr. Hans Keirstead, is the Board Chair of Mission Plasticos. Mission Plasticos is a non profit providing FREE reconstructive surgery to underserved populations in medical need. Please check out the segment from CBS2 News highlighting the importance of this life-changing work!
Immunis Chairman Dr. Hans Keirstead Meets With His Holiness the Dalai Lama [photos]
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, renowned neuroscientist Hans Keirstead, Ph.D., visited the Dalai Lama again this past week in His home in Dharamsala, India. The Dalai Lama remains a symbol of the unifying philosophy of Buddhism, where He is respected internationally as an educator of harmony and happiness for humanity.
Immunis Inc. Chairman, Dr. Hans Keirstead, presented a keynote at the 2022 Aging and Gerontology Conference in Dubai. Please enjoy the video footage of his keynote.
Immunis Chairman Dr. Hans Keirstead Presents at the Rejuvenation Startup Summit in Berlin [photos]
Immunis Inc Chairman, Dr. Hans Keirstead, delivered an exciting presentation about the potential of IMM01-STEM at the 2022 Rejuvenation Startup Summit in Berlin, Germany. The Immunis team is thrilled to share the following images of Dr. Keirstead in action.
Immunis, Inc., a private biotech company creating an innovative treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will deliver the keynote address at the Festival of Biologics Conference in Basel, Switzerland. The Festival of Biologics is one of the leading international events for drug discovery, development, manufacturing, pricing and market access for clinical trials.
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will present the keynote address at the Aging and Gerontology Conference in Dubai. The Aging and Gerontology Conference is a renowned international event that brings together longevity entrepreneurs, pharma and biotech companies, investors, researchers, and government organizations with the goal of extending human health span.
Immunis Chairman Dr. Hans Keirstead to Present at the Rejuvenation Startup Summit in Berlin
Immunis, Inc., a private biotech company producing a novel treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will deliver a presentation on the main stage at the 2022 Rejuvenation Startup Summit (RSS) in Berlin, Germany. The Rejuvenation Startup Summit is a leading networking event for translational researchers, rejuvenation startups and longevity investors.
Immunis, Inc., a private biotech company generating an innovative treatment for age and disease-related immune decline, announces that its Chairman, Dr. Hans Keirstead, delivered a keynote on behalf of the National Institute of Child Sexual Assault (NICSA) at the UN General Assembly in New York City. As part of Immunis’ ongoing Corporate Social Responsibility Program, Dr. Keirstead presented a keynote on child sexual assault (CSA), which aligns with the United Nation’s efforts to eradicate human trafficking and eliminate emotional, economical and physical violence against children and women.
Immunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board
Immunis Inc., a private biotechnology company developing an immunomodulatory secretome for age and disease-related immune decline in Phase 1/2a testing, welcomes Peter H. Diamandis, M.D. to the Executive Advisory Board. Dr. Diamandis received degrees in molecular genetics and aerospace engineering from MIT and is a Harvard-trained physician. His entrepreneurship has led to the creation of over 25 companies in the areas of space, education, venture capital and longevity.
Immunis, Inc., a private biotech company producing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., delivered a keynote to the United Nations (UN) as part of the AI for Good Global Summit. AI for Good is a digital platform helping innovators become educated in building and identifying practical AI solutions for the advancement of the UN’s “Sustainable Development Goals.”
Immunis Chairman Dr. Hans Keirstead Is Awarded Innovator of the Year [photo]
Immunis, Inc., a private biotech company developing a novel immunomodulatory secretome for age and disease-related immune degeneration, congratulates its Chairman, Hans Keirstead, Ph.D., on being recognized as the Orange County Business Journal’s 2022 Innovator of the Year. This annual award highlights the greatest innovators of Orange County who have generated groundbreaking products, treatments, services and business models.
Immunis Initiates Patient Enrollment for Muscle Atrophy Phase 1/2a Clinical Trial
Immunis Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, initiates patient enrollment for their Phase 1/2a clinical trial to assess Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy. Up to 18 patients ages 50-75 will participate in the clinical trial conducted at the University of California Irvine Medical Center, UCI Health, a facet of the California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network.
Immunis Signs Clinical Trial Agreement with CIRM Alpha Stem Cell Clinics
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has formally signed a clinical trial agreement with California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase 1/2a clinical trials. The trials will assess the safety and tolerability of Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease that is a leading cause of disability in elderly adults.
Immunis Publishes Research Study Showing Reversal of Aged Muscle Deficits
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, announced today the peer-reviewed publication of a research study conducted by Professor Micah J. Drummond at the University of Utah investigating the efficacy of Immunis’ immunomodulatory secretome product on aged skeletal muscle. The results were described in a GeroScience publication entitled “Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secretome product derived from partially differentiated human pluripotent stem cells.”
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it’s Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy: https://clinicaltrials.gov/ct2/show/NCT05211986
Immunis Closes $10 Million Financing Round
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has closed a $10M Series A First Closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Strategic investor, Continuum Health Ventures, which supports thesis-driven startups at the intersection of health and technology in the digital health and longevity sectors, also joined the round. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.
May 2022 FDA awards Phase 1/2a clinical trial to study the effects of Immunis’ platform immunomodulatory product STEM on muscular atrophy in patients with knee osteoarthritis